Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients

Daclizumab was approved by the FDA and the EMA in 2016 for the treatment of relapsing forms of multiple sclerosis (MS). Cases of severe inflammatory brain disease with fatal outcome led to the withdrawal of approval in Europe and the US on March 2, 2018. Approximately 8,000 patients worldwide receiv...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Neurol
Egile Nagusiak: Rommer, Paulus S., Berger, Klaus, Ellenberger, David, Fneish, Firas, Simbrich, Alexandra, Stahmann, Alexander, Zettl, Uwe K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Neurology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506133/
https://ncbi.nlm.nih.gov/pubmed/33013658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00996
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak